Although PARPis can lead to a ‘synthetic lethal’ interaction with HRD, the compensatory effects of other DNA damage repair pathways, BRCA1/2 recovery mutations, high expression of drug resistance pumps, and changes in tumor metabolism may cause acquired PARPi resistance [34]. The gene discussed is BRCA1; the disease is neoplasm.